Did You Ride The Rally In These Stocks?

(RTTNews) - It was a "Merger Monday" for the biotech sector yesterday, with two blockbuster acquisitions being announced.

Hyperion Therapeutics Inc.(HPTX), a commercial-stage biopharmaceutical company, is all set to be acquired by Horizon Pharma plc (HZNP) for $46.00 per share in cash or roughly $1.1 billion on a fully diluted basis.

Hyperion has two commercial products to treat Urea Cycle Disorders - RAVICTI Oral Liquid and BUPHENYL Tablets and Powder - both designed to lower ammonia in the blood.

RAVICTI was approved by the FDA in February 2013, and in May of that year, Hyperion acquired worldwide rights to FDA-approved BUPHENYL from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International Inc.

Net product revenue from sales of RAVICTI and BUPHENYL in the full year of 2014 was $113.58 million compared to $42 million in 2013.

We alerted our premium subscribers to HPTX on December 10, 2012 when it was trading around $10.31. Had you bought the stock then, you would have made a gain of more than 345% based on the per share consideration of $46 per share.

Another deal of the day is the acquisition of Auspex Pharmaceuticals Inc. (ASPX) by Teva Pharmaceutical Industries Ltd. (TEVA) for $101.00 per share in cash, representing total consideration of about $3.2 billion in enterprise value and roughly $3.5 billion in equity value.

Auspex' lead product candidate is Austedo, an inhibitor of protein vesicular monoamine transporter, for the treatment neurological disorders like Huntington's disease, Tourette syndrome and Tardive Dyskinesia.

The company completed target enrollment in a pivotal trial of Austedo in people with moderate to severe tardive dyskines in February of this year, and is on track to announce topline data from this study in mid-2015.

A phase 3 clinical trial of Austedo as a potential treatment for people with chorea associated with Huntington's disease has been completed, and the company plans to submit a New Drug Application under Section 505(b)(2) pathway for this indication by mid-2015.

We alerted our premium subscribers to ASPX on August 4, 2014 when it was trading around $17.11. Had you bought the stock then, you would have made a gain of 490% based on the per share consideration of $101 per share.

Cubist, acquired by Merck & Co. (MRK) for $102 a share, Idenix, also acquired by Merck for $24.50 a share, and Avanir acquired by Otsuka Pharmaceutical for $17 per share were the other stock picks we alerted our premium subscribers before the companies were bought out.